Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Tulodesvenlafaxine to relieve herpes zoster (shingles) pain

Official title: The Analgesic Efficacy and Safety of Oral Medications (Tulodsesvenlafaxine) in Patients With Herpes Zoster

Run by Beijing Tiantan Hospital · NCT07370389 · Data updated 2026-11-12

This trial tests whether adding tulodesvenlafaxine to standard care can reduce moderate-to-severe shingles pain in adults.

More Herpes Zoster trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment750 (estimated)
SponsorBeijing Tiantan Hospital
Academic / other
Locations1 site (Beijing)
StatusRecruiting
StartedDecember 15, 2025
Main results expectedSeptember 30, 2027
Study endsDecember 31, 2027
Registry record updatedJanuary 27, 2026
Trial IDNCT07370389 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged over 18 with a shingles rash that began less than 90 days ago, average pain of at least 4 on a 0–10 NRS, and adequate liver and kidney function who can consent and comply with visits.

Probably not a fit

Patients with disseminated or ocular herpes zoster, significant liver or renal impairment, prior tulodesvenlafaxine exposure, or those beyond the 90-day window may not benefit from this approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with recent herpes zoster (rash onset under 90 days) and moderate-to-severe pain (NRS ≥4) will receive standard antiviral/analgesic therapy either alone or combined with tulodesvenlafaxine, with liver and kidney function requirements for enrollment. The study compares pain scores and safety outcomes between the two groups over the treatment period. Patients with disseminated or ocular HZ, prior tulodesvenlafaxine use, or known hypersensitivity to the drug are excluded. The approach tests whether increasing central serotonin and norepinephrine availability can provide additional analgesia beyond conventional therapy.

Why it matters

Potential benefit: If successful, adding tulodesvenlafaxine could meaningfully reduce acute shingles pain and potentially lower the risk of longer-term postherpetic neuralgia while maintaining acceptable safety.

How similar studies have gone: Other antidepressants and SNRIs (for example duloxetine and venlafaxine) have shown analgesic effects in neuropathic pain and postherpetic neuralgia, but evidence specifically for acute herpes zoster pain is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 1\. Ages more than 18 years;
* 2\. Patients with onset of HZ rash less than 90 days;
* 3\. Experiencing moderate to severe HZ pain with an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10 = worst possible pain);
* 4\. Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal;
* 5\. Estimated glomerular filtration rate of 30 mL/min per 1.73 m2 or higher;
* 6\. Willing to sign the informed consent form and possessing sufficient cognitive and language abilities to comply with all the study requirements.

Exclusion Criteria:

* 1\. History of taking tulodesvenlafaxine;
* 2\. Patients with evidence of cutaneous or visceral dissemination of HZ infection (cutaneous dissemination is defined as more than 20 discrete lesions outside adjacent dermatomes) or ocular involvement of HZ;
* 3\. History of intolerance or hypersensitivity to any active components or excipient of the tulodesvenlafaxine;
* 4\. History of systemic immune diseases, organ transplantation, or cancers;
* 5\. Pregnancy or breastfeeding;
* 6\. Suffering from acute or chronic pain disorders other than HZ.

Where it's running

  • Beijing Tiantan Hospital, Beijing, Beijing 100070
    Beijing, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.